Correspondence roland.schuele@uniklinik-freiburg. de In Brief Duteil et al. find that BAT-selective Lsd1 ablation downregulates BAT-selective and upregulates WAT-selective gene expression. Lsd1 deletion shifts oxidative to glycolytic metabolism, resulting in whitening of BAT. Lsd1 maintains BAT properties in concert with the transcription factor Nrf1 and CoREST.
INTRODUCTION
Adipose tissue is an important metabolic regulator of energy balance (Langin, 2010) . In mammals, three types of adipose tissues exist. White adipose tissue (WAT) is essentially composed of white adipocytes containing one single large lipid vesicle. WAT is mainly located in the abdominal and subcutaneous areas of the body and is highly adapted to store excess energy in the form of triacylglycerides. Conversely, beige and brown adipocytes are highly energy-expending (Lee et al., 2014a) . They are able to dissipate energy in the form of heat via the action of uncoupling protein-1 (Ucp1) (Tiraby and Langin, 2003) . Brown adipocytes reside in discrete brown adipose tissue (BAT) depots, such as the interscapular area in rodents, whereas beige adipocytes are intermingled with white adipocytes in WAT. Both brown and beige adipocytes have a multilocular morphology and large numbers of mitochondria and express a common set of brown/beige fat-selective genes, including Ucp1 (Lee et al., 2014b) . In rodents, heat generated by brown or beige adipocytes via Ucp1 is essential to survive the cold season (Cohen and Spiegelman, 2015) . In both cell types, the cold response is mainly regulated by the sympathetic nervous system, in particular by the b3-adrenergic signaling pathway (Cannon and Nedergaard, 2004) . In addition to its role in thermogenesis and fatty acid oxidation, it has been reported that BAT activated by the b3-adrenergic signaling pathway can improve glucose homeostasis (Peirce and Vidal-Puig, 2013) .
Because recent studies have shown that brown/beige adipocytes exist in quantifiable amounts in humans (Betz and Enerbä ck, 2015) , these fat types have been rediscovered as potential therapeutic targets for weight loss. Therefore, understanding brown/beige adipocyte function and finding new ways to modulate their activity has become a major scientific point of interest (Betz and Enerbä ck, 2015) . Among other factors (Harms et al., 2014; Kleiner et al., 2012; Puigserver et al., 1998; Vernochet et al., 2012) , the epigenetic regulator lysine-specific demethylase 1 (Lsd1) (Cai et al., 2014; Metzger et al., 2005 , a flavin adenine dinucleotide (FAD)-dependent amine oxidase, has been shown to regulate the differentiation and function of white and beige adipocytes Musri et al., 2010) . In WAT, Lsd1 is induced by cold and involved in mediating the effects of b3-adrenergic signaling. Notably, we recently demonstrated that increased expression of Lsd1 in mouse WAT promotes the development of thermogenically active beige adipocytes and suppresses metabolic disorders such as obesity and type 2 diabetes . Moreover, in mature white adipocytes, elevation of Lsd1 levels is sufficient to activate mitochondria biogenesis, oxidative phosphorylation, and Scale bars, 5 mm (A) , 100 mm (D), 10 mm (E). See also Figure S1 and Table S1 .
Our data demonstrate that Lsd1 acts via a dual mechanism by positively regulating the expression of BAT-selective genes in cooperation with Nrf1 and actively repressing the expression of WAT-selective genes in concert with the CoREST complex. The whitening of BAT observed upon depletion or inhibition of Lsd1 is accompanied by a shift from oxidative to glycolytic metabolism associated with an accumulation of di-and triacylglycerides. This collapse of BAT function accelerates body weight gain but improves glucose tolerance. Taken together, our results demonstrate that Lsd1 is essential to maintain the metabolic function of brown adipose tissue.
RESULTS

Lsd1 Represses the White Fat Program in Brown Adipose Tissue
To investigate the role of Lsd1 in BAT, we crossed mice harboring conditional Lsd1 alleles (Zhu et al., 2014) with the Ucp1-Cre deleter strain (Turpin et al., 2014) , which resulted in Cre-mediated loss of Lsd1 selectively in brown and beige adipocytes (Lsd1 Ucp1-Cre , hereafter named Lsd1 cKO ) (Figures S1A and S1B). At 10 weeks of age, Lsd1 cKO mice exhibited a profound morphological whitening of their BAT ( Figure 1A ). This whitening was accompanied by an 40% increase in tissue mass ( Figure 1B ), a switch from multilocular to unilocular morphology, and increased lipid content (Figures 1D and 1E) . In Lsd1 cKO mice, the morphology of mitochondria was severely altered with substantially augmented size and less densely packed cristae ( Figure S1C ). In accordance, the DNA content of mitochondria was decreased by around 60% in Lsd1 cKO mice ( Figure S1D ), indicating degradation and dysfunction of this organelle. These observations suggested that loss of Lsd1 in brown adipocytes shifted BAT toward a white fat-like phenotype.
Accordingly, we expected to see changes in the transcriptional program of brown adipocytes of Lsd1 cKO mice that resemble the gene expression profile observed in white adipocytes. We therefore determined the transcriptome of Lsd1-deleted BAT and compared it with the transcriptome of WAT of control mice, which was described previously (Fitzgibbons et al., 2011 ; Figure 1F ; Table S1 ). The vast majority of WAT-selective genes (95%) was upregulated in BAT of Lsd1 cKO mice, whereas 67% of BAT-selective genes showed reduced expression ( Figure 1F ; Table S1 ). qRT-PCR analysis confirmed that the white fat transcriptome was enhanced to the detriment of the brown fat program, as illustrated by significantly increased expression of representative WAT-selective genes such as Bmp4, Egfr, Pdk3, Fads1, Apoe, Klhl13, Rtn1, Bmp1 , and Wls ( Figure 1G ) and decreased expression of representative BAT-selective genes (Ucp1, Slc27a2, Cox8b, Acadl, Cox6a1, Acadm, Oplah, Prdm16 , and Cox17) ( Figure 1H ) in Lsd1 cKO mice. In line with these RNA expression data, western blot analyses showed that BAT of Lsd1 cKO mice expressed higher levels of Apoe and reduced levels of Ucp1 protein ( Figure S1E ). These data suggest that, in BAT, Lsd1 is required to repress the expression of white fat-selective genes while supporting the brown fat-selective gene expression program.
Lsd1 Demethylase Activity Is Required to Maintain the Gene Expression Program of BAT in Mice
To determine whether Lsd1 demethylase activity is required to maintain the brown fat program, we engineered mice homozygous for a conditional, enzymatically inactive mutant Lsd1 knockin allele (Lsd1 KI/KI/Ucp1-Cre , hereafter named Lsd1 cKI ) . In BAT of these mice, the endogenous Lsd1 gene is replaced by an enzymatically inactive Lsd1 mutant allele following Ucp1-Cre-mediated recombination. As observed in Lsd1-depleted mice, we found that BAT of Lsd1 cKI mice was increased in size and contained a large proportion of unilocular adipocytes . Although Lsd1 mRNA levels remained unchanged ( Figure S1H ), the expression levels of WAT-selective genes were increased, whereas the levels of BAT-selective genes were decreased (Figures 1G and 1H; Figure S1I) . In conclusion, alterations in BAT morphology and transcription pattern in Lsd1 cKI mice resemble those of Lsd1 cKO mice, demonstrating that Lsd1 demethylase activity contributes to the phenotype observed in genetically modified mice. Because the expression of Ucp1 is initiated in utero between embryonic day (E) 18.5 and E19.5, Lsd1 ablation by Ucp1-Cremediated recombination is expected to occur around birth (Giralt et al., 1990) . To investigate the role of Lsd1 in adult BAT, 10-week-old wild-type mice were treated for 5 days with the Lsd1-specific nanomolar affinity inhibitor QC6688 (Lsd1(i)) or vehicle. BAT of mice treated with Lsd1(i) showed a profoundly pale color and increased size compared with that of vehicletreated mice (Figure 2A ; Figure S2A ). H&E staining of BAT sections revealed that Lsd1(i)-treated adipocytes had larger lipid droplets compared with those of vehicle-treated mice (Figure 2B) . The expression levels of representative WAT-selective genes were increased at both mRNA and protein levels ( Figures  2C and 2E ), whereas expression of representative BAT-selective genes was decreased in QC6688-treated mice (Figures 2D and 2E) . These data corroborate our findings in Lsd1 cKI mice and suggest that catalytically active Lsd1 is required to maintain the metabolic properties of BAT.
To investigate the cell autonomy of Lsd1(i) in BAT, we treated differentiated primary brown adipocytes (hereafter named brown adipocytes) isolated from the stromal vascular fraction with Lsd1(i) or vehicle for 3 days. As shown by oil red O staining, Lsd1(i)-treated brown adipocytes accumulated more fat than vehicle-treated cells ( Figure 2F ) and shifted their transcription pattern to a white adipocyte-like program ( Figures S2B-S2D ).
Together, these data demonstrate that the gene expression program of brown adipocytes is controlled by the catalytic activity of Lsd1 in a cell-autonomous manner.
Lsd1 Has a Dual Role in Controlling Expression of BATand WAT-Selective Genes
Next we determined genome-wide Lsd1 chromatin occupancy in brown adipocytes by chromatin immunoprecipitation using Lsd1 antibody followed by massive parallel sequencing (ChIPseq). The antibody was validated previously and specifically recognizes Lsd1 . We found that Lsd1 occupied the promoter of 75% of the BAT-selective genes (103 genes) and 68% of the WAT-selective genes (158 genes) differentially regulated in Lsd1 cKO mice ( Figure 2G ), suggesting a dual mechanism by which Lsd1 represses the expression of WAT-selective genes while activating that of BAT-selective genes. Hypergeometric optimization of motif enrichment (HOMER) motif searches revealed that promoter occupancy of Lsd1 significantly correlated with the presence of binding sites for the transcription factors Nrf1 and Rest ( Figure 2H ). Thus, we hypothesized that Lsd1 might positively regulate BAT-selective genes in cooperation with Nrf1 while repressing WAT-selective gene expression in concert with the CoREST complex. ChIP with Nrf1 antibody followed by qPCR analysis in brown adipocytes showed that Lsd1 and Nrf1 co-localized at promoters of representative BAT-selective genes such as Acadm, Oplah, and Cox6a1 ( Figure 3A) . Ucp1 was not part of the analysis because our genome-wide cistrome analysis by ChIP-seq showed no Lsd1 occupancy. Importantly, Nrf1 was not present at the promoter of WAT-selective genes, as illustrated by Figure S3A . Because Lsd1 is known to activate gene expression by erasing dimethyl groups at lysine 9 of histone 3 (H3K9me2), we hypothesized that inhibition of Lsd1 would modify methylation levels of H3K9 at BAT-selective genes. ChIP-qPCR analysis for H3K9me2 revealed that levels of H3K9me2 were increased upon Lsd1(i) treatment at promoters of BAT-selective genes ( Figure 3B ). In parallel, levels of H3K4me2 were reduced in Lsd1(i)-treated cells ( Figure S3B ), indicating a repressive transcriptional context. To investigate whether Lsd1 and Nrf1 are present in the same protein complex, nuclear extracts from brown adipocytes were subjected to size exclusion chromatography. Western blot analysis showed that Lsd1 and Nrf1 co-fractionate, suggesting the existence of an Nrf1/Lsd1complex ( Figure S3C ). Furthermore, Lsd1 and Nrf1 co-immunoprecipitated, confirming interaction between these two endogenously expressed proteins in BAT ( Figure S3D ). Accordingly, small interfering RNA (siRNA)-mediated knockdown of Nrf1 ( Figure S3E ) significantly decreased transcript levels of BAT-selective genes but did not impair WAT-selective gene expression ( Figure 3C ). Together, these data demonstrate that Lsd1 controls the expression of BATselective genes in cooperation with Nrf1 by targeting H3K9 methylation levels. Next we analyzed whether an Lsd1-associated repressor complex might regulate the WAT-selective gene program in BAT. For this purpose, nuclear protein extracts from BAT were used for immunoprecipitation with three distinct antiLsd1 antibodies directed against various Lsd1 domains followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The intersection of the three interactomes uncovered 163 proteins commonly interacting with Lsd1 ( Figure S3F ) and revealed the repressive CoREST complex as a significantly enriched protein group (Table S2) . Interaction between Lsd1 and CoREST has already been well established (Lee et al., 2005; Metzger et al., 2005; Shi et al., 2004) . Accordingly, co-immunoprecipitation experiments and size exclusion chromatography demonstrated that, also in BAT, endogenous Lsd1 interacts with members of the CoREST complex (Figures S3G and S3H) . To test whether the CoREST complex indeed represses the expression of WAT-selective genes, we knocked down the complex members Rcor1 and Rcor3 in brown adipocytes ( Figure S3I ). Cells treated with Rcor1 or Rcor3 siRNA upregulated WAT-selective genes ( Figure 3D ) without affecting BAT-selective genes, as exemplified by Oplah and Acadl ( Figure 3D ), and accumulated more lipids than cells treated with control siRNA ( Figure S3J ). In addition, ChIP-qPCR analyses confirmed the colocalization of Rcor1 and Rcor3 with Lsd1 specifically at promoters of WAT-selective genes ( Figure 3E ) but not at promoters of BAT-selective genes Figure S3K ). Because Lsd1 is known to repress gene expression by erasing dimethylation of lysine 4 of histone 3 (H3K4me2), we analyzed whether inhibition of Lsd1 is sufficient to alter methylation levels of H3K4 at WAT-selective genes. ChIP-qPCR analysis showed that levels of H3K4me2 were increased upon Lsd1(i) treatment at promoters of WAT-selective genes (Figure 3F) . Concomitantly, levels of H3K9me2 were decreased at these promoters ( Figure S3L) Figure 4A ) uncovered pathways regulating energy production and fatty acid catabolism such as the tricarboxylic acid (TCA) cycle, electron transport chain (ETC), and b-oxidation. The expression of genes representing these pathways was downregulated ( Figure 4B ; Figure S4A ), suggesting that oxidative metabolism is lowered in BAT of Lsd1 cKO mice, confirming our data in WAT . Interestingly, the second most enriched pathway was ''glycolysis and gluconeogenesis,'' which we did not observe in WAT. In line with these findings, we observed increased expression of glucose transporters and the majority of glycolytic enzymes catalyzing glucose-to-pyruvate conversion in Lsd1 cKO mice (Figure 4B ; Figure S4B ). We thus hypothesized that Lsd1 deficiency in BAT not only leads to reduction of oxidative functions but also increases glycolytic capacities. To evaluate bioenergetic changes upon inhibition of Lsd1, we employed a Seahorse XF analyzer (Agilent Technologies) to measure the extracellular acidification rate (ECAR) as an index of glycolytic activity (using a glycolysis stress kit) and the oxygen consumption rate (OCR) as an index of respiratory capacity (using the Cell Mito stress test kit) in brown adipocytes treated with Lsd1(i) or vehicle. The rate of glycolysis following glucose administration was higher upon Lsd1(i) treatment compared with vehicle ( Figure 4C ; Figure S4C ). After addition of oligomycin, an inhibitor of mitochondrial ATP synthesis, the maximum glycolytic capacity of Lsd1(i)-treated cells remained higher than in control cells, demonstrating that not only the rate of glycolysis but also the glycolytic reserve capacity were enhanced in Lsd1-inactivated cells ( Figure 4C ; Figure S4C ). In parallel, the OCR was lower in Lsd(i)-treated cells compared with vehicle ( Figures  S4D and S4E) , and, subsequently, the OCR/ECAR ratio was decreased, demonstrating that Lsd1 inhibition shifted mitochondrial metabolism toward the glycolytic pathway in brown adipocytes ( Figure 4D ). Furthermore, oxygen consumption resulting from mitochondrial respiration measured in BAT of Lsd1 cKO mice was reduced compared with control mice, confirming lower oxidative phosphorylation ( Figure S4F ). Taken together, our data show that glycolytic activity is enhanced in the absence of Lsd1, whereas oxidative phosphorylation is reduced. In addition, glucose uptake and activity of key glycolytic enzymes such as hexokinase (Hk), phosphofructokinase (Pfk), enolase (Eno), and lactate dehydrogenase (Ldh) were higher in BAT of Lsd1 cKO mice compared with control mice ( Figure 4E ), promoting increased glycolytic capacity. Of note, the expression levels of genes involved in pyruvate metabolism, including the rate-limiting mitochondrial pyruvate transporters (Mpc1 and Mpc2) and enzymes catalyzing the conversion from pyruvate to acetyl-coenzyme A (CoA) (e.g., Dlat and Pdhx), were decreased in Lsd1 cKO mice ( Figure 4B ; Figure S4G ).
Our genome-wide analysis also revealed that expression of glutamic-oxaloacetic transaminase 1 (Got1) and 2 (Got2) as well as Slc25a12 and phosphoenolpyruvate carboxykinase 2 (Pck2) was upregulated in Lsd1 cKO mice compared with control (Figure 4B ; Figure S4G ). Got1 and 2 are responsible for conversion of downstream pyruvate intermediate oxaloacetate into aspartate and phosphoenolpyruvate, respectively (Birsoy et al., 2015) . In particular, Got1 was shown to be essential for aspartate regeneration to restore ETC dysfunction (Birsoy et al., 2015) . ETC dysfunction is associated with a drop in nicotinamide adenine dinucleotide (NAD + )/NADH ratio because NAD + cannot be oxidized by complex I. However, despite decreased oxidative phosphorylation (OXPHOS), the NAD + /NADH ratio was increased in BAT of Lsd1 cKO mice ( Figure S4H ). This might be, at least in part, mediated by higher Got1 activity ( Figure 4E ). An Increased NAD + /NADH ratio is also in favor of increased glycolysis (Zhang et al., 2007) .
Similarly, expression profiling of metabolic genes in Lsd1 cKI mice and mice treated with Lsd1(i) revealed that Lsd1 demethylase activity strongly contributes to maintaining proper energy metabolism in BAT ( Figures S4B, S4G , and S4I). Taken together, these data show that glycolysis is enhanced in Lsd1-inactivated BAT, whereas oxidative metabolism is lowered. The analysis of genome-wide Lsd1 chromatin occupancy in BAT by ChIP-seq revealed that glucose transporters and genes 
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(legend on next page) involved in glycolysis are direct targets of Lsd1 ( Figure S4J ). ChIP-qPCR of brown adipocytes showed promoter occupancy of representative genes by Rcor1, Rcor3, and Lsd1 ( Figure 4F ). In parallel, the levels of H3K4me2 were enriched, whereas the levels of H3K9me2 were lowered upon Lsd1(i) treatment (Figure 4G; Figures S4K and S4L ). These results demonstrate that Lsd1 is directly repressing glycolytic genes to ensure physiological metabolic processes in brown adipocytes.
Lsd1 Regulates Lipid Accumulation in BAT
To further investigate our phenotype, we performed metabolomic and lipidomic analyses of BAT of 10-week-old control and Lsd1 cKO mice. These analyses revealed an accumulation of intermediates of glycolysis, including glyceraldehyde-3-phosphate and glycerol, in BAT of Lsd1 cKO mice ( Figure 5A ) accompanied by augmentation of long-chain diacyl-and triacylglycerides (DAGs and TAGs, respectively) ( Figure 5B ). In accordance with an increase in long-chain fatty acids, the transcript levels of fatty acid elongases (Elovl1, Elovl4, and Elovl7) and fatty acid desaturases (Fads1 and Fads2) were upregulated in the absence of Lsd1 (Figures 4B and 5C) or Lsd1 demethylase activity ( Figures S5A and S5B ). The analysis of genome-wide Lsd1 chromatin occupancy in BAT by ChIP-seq revealed that genes encoding enzymes involved in fatty acid elongation are direct targets of Lsd1 ( Figures S5C-S5F ). DAG and TAG are glycerol esters derived from dihydroxyacetone phosphate (DHAP) and fatty acids. Allocation of fatty acids necessary for glyceride synthesis might be due to decreased lipolysis, increased de novo lipogenesis, or increased fatty acid uptake in BAT of Lsd1 cKO mice. Increased fatty acid synthase (Fasn) activity ( Figure 5D ) and low acetyl-CoA carboxylase phosphorylation ( Figure S5G ) are in favor of enhanced de novo lipogenesis in Lsd1 cKO mice. To assess lipolysis efficiency, we measured lipase activity. The activity of lipases present in brown adipocytes was reduced by 50% in Lsd1 cKO mice, suggesting that hydrolysis of lipids into fatty acids is severely impaired (Figure 5E) . In addition, the activity of lipoprotein lipase (Lpl), which hydrolyzes triglycerides in lipoproteins such as those found in chylomicrons and very low-density lipoprotein (VLDL) to facilitate fatty acid uptake from the bloodstream, was increased upon loss of Lsd1 ( Figure 5F ). Finally, to test whether fatty acid oxidation was altered, we measured mitochondrial respiration in the presence of palmitoyl-L-carnitine as substrate in saponine-permeabilized BAT. The data revealed that Lsd1-deficient BAT failed to properly use fatty acids ( Figure 5G ). Increased fatty acid synthesis and lower lipolysis are in agreement with the observation of an increased NAD + /NADH ratio ( Figure S4H ).
Altogether, these findings show that Lsd1 regulates lipid accumulation in BAT. In summary, our data show that Lsd1 positively regulates the expression of oxidative metabolism-related genes with concomitant repression of the gene program responsible for glycolysis and fatty acid biosynthesis. Accordingly, loss of Lsd1 in brown adipose tissue drives a shift from oxidative to glycolytic metabolism accompanied by aberrant triglyceride accumulation.
Absence of Lsd1 Improves Glucose Uptake Despite Increasing Body Weight Finally, we examined the consequences of Lsd1 loss in BAT with aging. Lsd1 cKO male mice gained significantly more weight (40%) than their control littermates between 10 and 30 weeks of age ( Figure 6A ). No weight differences were observed in females ( Figure S6A ). The weight gain of Lsd1 cKO mice was not due to increased food intake or decreased mobility ( Figures  S6B-S6D ). Body composition analysis assessed with a wholebody magnetic resonance analyzer (EchoMRI) revealed that 30-week-old Lsd1 cKO mice accumulated more fat than their control littermates, resulting in a lower lean/fat mass ratio compared with control mice ( Figure 6B ). These data were corroborated by a dramatically increased BAT mass in 30-week-old Lsd1 cKO mice as well as in Lsd1 cKI mice (Figures S6E and S6F) , associated with 45% augmentation in fatty acid content of BAT ( Figure 6C ). In accordance, histological analyses revealed a robust phenotypic conversion of BAT in Lsd1 cKO and Lsd1 cKI mice to a WATlike appearance ( Figure S6G ). In addition, we noticed robustly reduced Ucp1 protein levels, as shown by immunocytochemistry ( Figure S6G ). Observed morphological changes in BAT are accompanied by increased levels of intermediates of glycolysis, glycerol, DAG, and TAG (Figures S6H and S6I) . In 30-week-old Lsd1 cKO mice, we observed lower energy expenditure, determined by decreased whole-body oxygen consumption (VO 2 ) ( Figure 6D ; Figures S6J and S6K) and CO 2 production (VCO 2 ) ( Figure 6E ; Figures S6L and S6M), resulting in an increased respiratory quotient (RQ, VCO 2 /VO 2 ratio) (Figure 6F ). This confirmed a shift in fuel consumption from fatty acids to carbohydrates. In addition, calorimetric parameters deduced from these analyses indicated that energy expenditure was decreased in Lsd1 cKO mice ( Figure 6G ; Figures S6N and   S6O ). This was confirmed by body temperature measurements ( Figure 6H ). Next we analyzed mice for glucose tolerance and insulin sensitivity. We observed that circulating glucose levels in 10-week-old Lsd1 cKO mice were lower compared with control littermates (Figure 6I ). Nevertheless, we did not notice any difference in glucose tolerance of Lsd1 cKO mice relative to control mice at this age ( Figure 6J ). Importantly, with aging, control mice developed progressive glucose intolerance, contrary to Lsd1 cKO mice, which conserved efficient glucose uptake ( Figure 6J ). Age-developed glucose intolerance is generally associated with loss of insulin sensitivity and contributes to type 2 diabetes. To unravel whether Lsd1 cKO mice are resistant to age-induced type 2 diabetes, we performed an intraperitoneal insulin sensitivity test (IPIST) and determined serum insulin levels. Despite dramatic alterations in glucose metabolism, we did not observe any difference in insulin Cell Reports 17, 1008-1021, October 18, 2016 1017 sensitivity ( Figure S6P ) or in total insulin levels ( Figure S6Q) , showing that only glucose but not insulin metabolism is altered in Lsd1 cKO mice. In summary, these data show that Lsd1 is required in BAT to maintain a proper energy balance with aging.
DISCUSSION
White and brown adipocytes have distinct transcriptional programs that facilitate long-term lipid storage or thermogenesis, respectively. Understanding these programs is of the highest interest for developing new strategies to counteract obesity. The epigenetic determinants that regulate white versus brown fat-selective gene expression have not yet been completely elucidated. In this study, we show that the histone demethylase Lsd1 plays a key role in the maintenance of brown fat metabolic properties. Lsd1 accomplishes this mission via a dual mechanism by inhibiting the expression of WAT-selective genes and simultaneously promoting the expression of BAT-selective genes. These opposing functions of Lsd1 are orchestrated by the assembly in different protein complexes: a repressive CoREST complex to inhibit the expression of WAT-selective genes and an Nrf1-containing complex to promote the expression of BAT-selective genes ( Figure 7 ). Our data point out the importance of Lsd1 demethylase activity in controlling BAT metabolism in vivo. (Lee et al., 2005; Metzger et al., 2005; Shi et al., 2004; Yang et al., 2011) , the physiological function of CoREST in vivo remains unclear. Here we demonstrate for the time that the CoREST complex plays a critical role in the repression of the WAT-selective genes in BAT, thereby strongly contributing to the maintenance of brown fat characteristics. In BAT, Lsd1 specifically associates with Rcor1 and Rcor3 but not Rcor2. Similar to Lsd1, Rcor1 is ubiquitously expressed in somatic cells, whereas the expression of Rcor2 and Rcor3 seems to be more restricted (Yang et al., 2011) . This suggests that the Lsd1 corepressor complex might assemble with different Rcor family members to carry out specific functions in different cell types.
Furthermore, Lsd1 interacts with Nrf1 to activate the expression of BAT-selective genes. We have shown previously that, in WAT, Lsd1 acts together with Nrf1 to positively regulate OXPHOS and thermogenesis . Elevated Lsd1 levels favor beigening of WAT by increasing oxidative metabolism, uncoupling, thermogenesis, and the number and size of mitochondria. Our data provide evidence that the absence of Lsd1 in BAT causes dramatic mitochondrial dysfunction associated with decreased transcript levels of OXPHOSrelated genes. It is interesting that Lsd1 in cooperation with Nrf1 shares comparable functions in beige and brown adipocytes. Whether the mechanism of regulation of oxidative metabolism is conserved in all metabolically active tissues remains unclear. To clarify this hypothesis, it would be necessary to analyze the metabolism of skeletal muscle and liver in Lsd1 knockout mice.
Our analyses uncovered that Lsd1 is necessary to regulate metabolism, particularly fatty acid oxidation, de novo lipogenesis, and lipolysis, leading to increased DAG and TAG accumulation and whitening of Lsd1 cKO BAT. In addition, Lsd1 depletion/ inhibition leads to elevated glucose uptake and increased glycolytic capacities in mice. This may contribute to DAG and TAG accumulation because the glycerol backbone for triglyceride synthesis can be derived from the glycolytic intermediate dihydroxyacetone phosphate. Furthermore, pyruvate is converted into citrate in the TCA cycle and utilized to provide acetyl-CoA to initiate de novo lipogenesis. However, further experiments would be necessary to provide a direct link between these processes. Nevertheless, the role of Lsd1 in lipid metabolism has been confirmed in this study because Lsd1 cKO mice show increased activity of fatty acid synthase and decreased activity of lipases. Altogether, alterations in glycolysis and fatty acid oxidation might contribute to aberrant production of DAG and TAG, which leads to increased fat accumulation. Transcriptional and metabolic changes induced by Lsd1 ablation have secondary effects on body weight gain and glucose tolerance with aging. Indeed, Lsd1 cKO mice gained significantly more weight than their control littermates. These findings are of interest, considering that many mouse models possessing defects in adipose tissue function and metabolism, such as loss of mitochondrial uncoupling (Liu et al., 2003) and fatty acid or ceramide metabolism (Ellis et al., 2010; Lee et al., 2016; Schoiswohl et al., 2015; Turpin et al., 2014) , do not develop obesity. A hypothesis might be that Lsd1-deficient brown adipocytes secrete signaling molecules that exert a potential inhibitory function on energy expenditure in other metabolic organs such as white adipose tissue, liver, or muscle. Consequently, we carefully inspected our transcriptome analysis for differential expression of endocrine molecules, cytokines, or other signaling molecules. This analysis failed to identify any known candidates that might explain the phenotype in our mice. This, however, does not exclude the possibility that Lsd1 regulates the expression of yet undescribed endocrine molecules in brown adipocytes. Future studies will be required to elucidate this issue. Previous studies showed that the ablation of the brown fat-determining transcriptional regulator Prdm16 is required to suppress the expression of WAT-selective genes in BAT (Harms et al., 2014) similar to Lsd1. However, the expression of the most typical BAT-selective genes was only slightly reduced upon Prdm16 ablation, which could explain why Prdm16 knockout mice are not prone to obesity (Harms et al., 2014) . In line with this publication, Zeng et al. (2016) showed that Lsd1 associates with Prdm16 to repress expression of WAT-selective genes. Of note, our ChIP-seq data identified Prdm16 as a direct Lsd1 target, and Prdm16 expression was reduced in Lsd1-deleted BAT. However, immunoprecipitation, size exclusion chromatography, and mass spectrometry analyses did not provide any evidence for association of Lsd1 and Prdm16 in BAT, suggesting that Lsd1 acts upstream of Prdm16. Zeng et al. (2016) also claim that Lsd1 represses the expression of hydroxysteroid 11-b-dehydrogenase isozyme 1 (Hsd11b1) independently from Prdm16. Even though Hsd11b1 is 1.5-fold upregulated in our Lsd1 cKO mice, our cistrome analysis did not provide any evidence for binding of Lsd1 to the Hsd11b1 promoter. Even though the phenotypes of our Lsd1 cKO mice and the mice engineered by Zeng et al. (2016) are close, the differences observed in the follow-up cistrome and transcriptome analyses and the interpretation of the molecular mechanism could be explained by the fact that they did not use a brown fat-specific Cre deleter strain. Recently, Sambeat et al. (2016) proposed that Zfp516 associates with Lsd1 to promote Ucp1 promoter occupancy and gene expression. In clear contrast, our mass spectrometry analysis does not confirm interaction of endogenously expressed Lsd1 and Zfp516 in brown adipocytes. In addition, our ChIP-seq showed that the Ucp1 promoter is not occupied by Lsd1 in brown adipocytes.
Our findings indicate that the use of Lsd1 inhibitors would lead to a shift from oxidative to glycolytic metabolism in BAT, resulting in weight gain but improved glucose tolerance. These findings need to be considered because Lsd1 inhibitors entered clinical trials, for example in the treatment of mixed-lineage leukemia (Feng et al., 2016) . In conclusion, our data identify Lsd1 as a key epigenetic regulator of BAT metabolism.
EXPERIMENTAL PROCEDURES
Mouse Studies All mice were housed in the pathogen-free barrier facility of the University Medical Center Freiburg in accordance with institutional guidelines approved by the regional board. Mice were maintained in a temperature-and humiditycontrolled animal facility with a 12-hr light/dark cycle, free access to water, and a standard rodent chow (Kliba, breeding, 3807). Male mice were analyzed at 10 or 30 weeks of age. Animals were killed by cervical dislocation, and tissues were immediately collected, weighed, frozen in liquid nitrogen, or processed for further analyses. In vivo experiments, including food consumption, serum analysis, glucose tolerance tests, temperature measurements, and energy expenditure, were described previously . The Lsd1 inhibitor QC6688 was administrated per os at 5 mg/kg in 0.5% methylcellulose (Sigma; product M0512-110G; viscosity, 4,000 centipoise [cP]).
Cellular Metabolism
Cellular metabolic rates were measured using an XF24 analyzer (Seahorse Bioscience). Immediately before the measurement, cells were washed with unbuffered DMEM as described previously (Wu et al., 2007) . Plates were placed into the XF24 instrument for measurement of OCR and ECAR with the XFp glycolysis stress kit (103017-100, Seahorse) for ECAR measurements (glucose, 10 mM; oligomycin, 1 mM; and 2 deoxiglucose (2-DG), 50 mM) or the Cell Mito stress kit (103010-100, Seahorse) for OCR measurements (oligomycin, 1 mM; carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), 0.5 mM; and rotenone/antimycin A, 0.25 mM).
Lipid Quantification
Total lipids were extracted from 50 mg of BAT using a lipid extraction kit (STA-612, Cell Biolabs) and quantified using a lipid quantification kit (STA-613, Cell Biolabs) according to the manufacturer's recommendations.
Quantification of Mitochondrial and Nuclear DNA BAT was digested overnight with Proteinase K, and DNA was extracted with phenol-chloroform. Mitochondria and nuclear DNA were amplified by qPCR using Cox2 and Fasn primers (Table S4) , respectively.
Metabolomic and Lipidomic Analyses
Tissue samples were grinded with a Retsch MM440 instrument and further extracted as described in . LC-MS measurements were performed using a Waters ACQUITY ultra performance liquid chromatography (UPLC) system coupled to a Thermo Fisher Scientific QExactive mass spectrometer. Details of the analysis are presented in the Supplemental Experimental Procedures.
Data Analysis
Data are represented as mean + SEM. Significance was calculated by (1) two-tailed Student's t test for Figures 1G and 1H , 2C and 2D, 4D and 4E, 5C-5G, and 6C-6I and Figures S1A, S1D, S2A, S2C, S2D, S4B, S4C, S4E-S4I, S5A, S5B, S6B-S6E, S6J, S6L, S6N, and S6Q; (2) one-way ANOVA for Figures 3A and 3C Heatmaps were generated by centering and normalizing expression values with Cluster 3.0 and importing them to MeV viewer.
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The accession numbers for the RNA-seq and ChIP-seq data reported in this paper are GEO: GSE81557 and GEO: GSE81557, respectively. The accession number for the mass spectrometry proteomics data reported in this paper is ProteomeXchange Consortium/PRIDE (Vizcaíno et al., 2016) partner repository: PXD004745. (E) Relative mRNA levels of Lsd1 and Nrf1 in brown adipocytes transfected with siRNA Ctrl, siRNA Lsd1, or siRNA Nrf1 (mean + SEM, n = 3). In agreement with previous data , knock-down of Lsd1 results in reduced mRNA levels of Nrf1. (F) Venn diagram depicting the overlap between Lsd1 interacting proteins identified by immunoprecipitation using three different Lsd1 antibodies followed by mass spectrometry. Ab1 and Ab2 correspond to 2 homemade anti-Lsd1 antibodies (see Experimental procedures for details) and Ab3 corresponds to the L-4481 (Sigma) anti-Lsd1 antibody. 
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OXPHOS
Glut3 (B) Relative mRNA levels of genes encoding glucose transporters and glycolytic enzymes in BAT of Ctrl, Lsd1 cKO , and Lsd1 cKI mice [mean + SEM, *p<0.05, **p<0.01, ***p<0.001, Ctrl (black bars) n = 9, Lsd1 cKO (orange bars) n = 7, Ctrl (white bars) n = 7, and Lsd1 cKI (red bars) n = 6]. (C) Glycolysis, maximal glycolytic capacity and glycolytic reserve deduced from extracellular acidification rate (ECAR) (mean + SEM, *p<0.05, n = 6). (D-E) Oxygen consumption rate (OCR) of vehicle-or Lsd1(i) treated brown adipocytes determined by the Seahorse Extracellular Flux Analyzer (mean + SEM, *p<0.05, n = 9). (F) Mitochondrial respiration of BAT extracts from Ctrl and Lsd1 cKO mice assessed with a high-resolution respiratory Oxygraph-2K system (mean + SEM, **p<0.01, n = 5). (G) Relative mRNA levels of genes encoding glycolytic and pyruvate processing enzymes in BAT of Ctrl, Lsd1 cKO , and Lsd1 cKI mice [mean + SEM, *p<0.05, **p<0.01, ***p<0.001, Ctrl (black bars) n = 9, Lsd1 cKO (orange bars) n = 7, Ctrl (white bars) n = 7, and Lsd1 cKI (red bars) n = 6]. (H) Determination of the NAD + /NADH ratio in BAT of Ctrl and Lsd1 cKO mice at 10 weeks of age (mean + SEM, **p<0.01, ***p<0.001, n = 6). (I) Relative mRNA levels of selected genes encoding glucose transporters, glycolytic, and pyruvate processing enzymes in BAT of mice treated with vehicle or Lsd1(i) [mean + SEM, *p<0.05, **p<0.01, ***p<0.001, Vehicle n = 6, Lsd1(i) n Tables   Table S1 ( Figure 3) . List of the 163 Lsd1 interacting proteins identified by immunoprecipitation followed by mass-spectrometry. The calculation of log2-value is described in Materials and Methods. Table S3 (related to Figure S1 ). Primers used for genotyping Table S4 . Primers used for qPCR analysis
Gene Sense Primer 5'-3'
Lsd1 WT/L2 fw CCTCAGTAGGCCTGGTTTGT Lsd1 WT/L2 rev TTGGTTTTGGTTGACCCTTC Lsd1 L- fw CCGTGGAAATTCGTGCACTC Lsd1 L- rev GCAGGCGGTTTGAAATGTATTC Lsd1 WT/KI fw CCAGCTGCTTGTTGGTGC Lsd1 WT/KI rev TGGAGTGAAGTGGTTACCTGC Ucp1-Cre fw CCTCTGCACTGGCACTACCT Ucp1-Cre rev TCTTCTTCTTGGGCACCATC
Supplemental Experimental Procedures
Generation of conditional Lsd1 knock-out and knock-in mice All experiments were performed in C57/Bl6N background. The targeting strategy for the conditional deletion of the first exon of Lsd1 ( Lsd1 tm1Schüle ) is available upon request (Zhu et al., 2014) . Briefly, conditional Lsd1 mice were mated with Ucp1-Cre mice to selectively ablate Lsd1 in brown adipose tissue ( Figures S1A and S1B ). Homozygous conditional mice were used as controls. Mice were genotyped with primers for detection of conditional Lsd1 alleles and Cre recombinase (Table S3) . Lsd1 knock-in (KI) mice were generated by Taconic [C57BL/6-Kdm1a tm2931(K662A, W752A, Y762S)Arte ]. The targeting vector has been engineered as follows ( Figure S1F ). Wild-type Lsd1 exons 15 to 19, including the complete 3' untranslated region (UTR), were flanked by loxP sites. An additional polyadenylation signal (hGHpA: human Growth Hormone polyadenylation signal) was inserted between the 3' UTR and the distal loxP site in order to prevent downstream transcription of the mutated Lsd1 exons 15 to 19. The size of the loxP-flanked region is 5.1 kb. Exons 15 to 19, including the splice acceptor site of intron 14, were duplicated and inserted downstream of the distal loxP site. Intron 15 was removed from the wild-type and the duplicated region in order to create a fusion of exon 15/16. K662A mutation was introduced into the duplicated exon 15, W752A and Y762S mutations were introduced into the duplicated exon 18. A second hGHpA cassette was inserted downstream of the duplicated 3' UTR. Positive selection markers were flanked by FRT (Neomycin resistance) and F3 (Puromycin resistance) sites, and inserted into intron 14 and downstream of the second hGHpA, respectively. The targeting vector has been generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and transfected into the Taconic Artemis C57BL/6N Tac ES cell line. Homologous recombinant clones were isolated using double positive (NeoR and PuroR) selection (in order to increase the efficiency of co-integration of both loxP sites and the point mutations). Figure S1G and Table S3 ).
RNA preparation, qRT-PCR, and RNA sequencing (RNA-seq) RNA was isolated with TRIzol Reagent (Invitrogen) and processed as described . Data were analyzed using the standard curve method (Bookout et al., 2006) . 36b4, Hprt, or β-actin were used for normalization. Primer sequences are given in Table S4 . RNA samples were sequenced by the standard Illumina protocol to create raw sequence files (.fastq files). We annotated these reads to the mm10 build of the mouse genome using TopHat version 2. The aligned reads were counted with the homer software (analyze RNA) and DEGs were identified using EdgeR and DESeq version 1.8.3. Differentially regulated genes (reads > 50, p < 0.01) were further used for pathway analysis in WebGestalt (Heinz et al., 2010; Wang et al., 2013) .
Protein analyses
Western blot analysis, co-immunoprecipitation assays, gel filtration, and mass spectrometry experiments were performed as described . For gel filtration, brown adipocytes were harvested and suspended in isolation buffer (10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, and complete protease inhibitor cocktail, Roche), allowed to swell on ice for 10 min, and pelleted. Isolated nuclei were resuspended in 20 mM HEPES-KOH, pH 7.9, 25 % glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, and complete protease inhibitor cocktail, incubated on ice for 20 min and centrifuged at 14,000 r.p.m. for 10 min. Nuclear complexes were separated by gel filtration on a Superose 6 TM 10/300 GL column (GE Healthcare) using the ÄKTA pure 25 system (GE Healthcare). The void volume was 7.2 mL. 60 fractions of 300 µL were collected from an elution volume of 4.8 mL. The gel filtration buffer was composed of 50 mM KCl, 50 mM NaCH 3 COOH, pH 7.2 including protease inhibitors and phosphatase inhibitors (Roche Diagnostics). Column calibration was done using carbonic anhydrase (26 kDa), bovin serum albumin (66 kDa), alchol dehydrogenase (150 kDa), b-amylase (200 kDa), apoferritin (443 kDa), and thyroglobulin (669 kDa) as markers according to the method provided by the supplier. Western blot membranes were decorated using following antibodies: anti-Lsd1 [3544 , Schüle laboratory , 1/1000], anti-Ucp1 (Abcam, ab10983, 1/1000), anti-Apoe (Santa Cruz, M-20, 1/200), anti-Nrf1 (Abcam, ab55744, 1/500), anti-Hdac1 (Abcam, ab7028-50, 1/1000), anti-Hdac2 (Santa Cruz, sc-7899, 1/2500), anti-Rcor1 (Abcam, ab32631, 1/400), anti-Rcor3 (Abcam, ab76921, 1/2000), anti-Arid1a (Santa Cruz, sc-373784, 1/200), anti-phosphoAcc (Cell signaling, 11818, 1/1000), anti-Acc (Cell signaling, 3676, 1/1000), anti-b-Tubulin (Sigma, T6074, 1/10000), and anti-b-Actin (Sigma, A1978, 1/10000). Secondary antibodies conjugated to horseradish peroxidase (GE Healthcare) were detected using an enhanced chemiluminescence detection system (GE Healthcare). For immunoprecipitation assay, 500 mg of protein extracts were incubated with 5 µg of anti-Lsd1 (Sigma, L-4481) and processed as described (Metzger et al., 2010) . Mass spectrometry experiments were performed as described . Lsd1 antibodies used for immunoprecipitation were Sigma L-4481 (Ab3 in Figure S3F ), and the two Lsd1 antibodies 20752 and 3544 (Ab1 and Ab2 in Figure S3F , respectively) that we previously characterized . The number of peptides obtained for each protein after Lsd1 immunoprecipitation was subtracted from the number of peptides obtained with IgG. The resulting number was then normalized to the number of Lsd1 peptides on a log2 basis. The calculation of log2-value is presented in Table S2 . GO cellular component analysis was performed using the Panther algorithm (Ashburner et al., 2000) .
Primary cell isolation and cell culture BAT was cut in small pieces and incubated with 2 mg/ml collagenase I (CLS-1, Worthington) for 45 min. The cell suspension was filtered through a 150 µm nylon mesh and the stromal-vascular fraction (SVF) was isolated by low-speed centrifugation. For FACS analysis, the erythrocyte-free SVF was incubated with a mix of antibodies against different surface markers as described previously Wu et al., 2012) and sorted using an Aria flow cytometer (BD Biosciences). Dead cells were removed using DAPI staining (1/10000). Primary adipocytes were cultured in DMEM High Glucose containing 20 % fetal calf serum (FCS) and 2 % of 1 M Hepes buffer in dishes coated with collagen. Alternatively, preiBA cells were cultured in DMEM containing sodium pyruvate and glutamine (GIBCO 11995-065) supplemented with 10 % FCS. Differentiation of primary adipocytes and preiBA cells was induced by treatment of confluent cells with an adipogenic mixture consisting of 850 nM insulin (Gibco), 1 µM dexamethasone (Calbiochem), 1 µM rosiglitazone (Cayman), 125 nM indomethacin (Sigma), 1 nM T3 (Sigma), and 500 µM isobutylmethylxanthine (Serva) in the presence of 10 % FCS. The differentiation medium was replaced 2 days later with medium supplemented with 10 % FCS, 850 nM insulin, and 1 nM T3 for 2 days. Subsequently, cells were cultured in the same medium for 4 more days and considered as differentiated. Differentiated cells were transfected with 1 mM siRNA against Lsd1, Nrf1, Rcor1, Rcor3, or unrelated control (Invitrogen) using Lipofectamine RNAimax (Invitrogen) according to the manufacturer's instructions. siRNA oligonucleotide sequences were as follows: Lsd1 siRNA: 5'-CCCAAAGAUCCAGCUGACGUUUGAA-3'; Nrf1 siRNA: 5'-UAUGGUAGCCAUGUGUUCAGUUUGG-3'; Rcor1 siRNA: 5'-GCGCAGUCAAGAACGAGACAAUCUU-3'; Rcor3 siRNA: 5'-UCCCAGAUGCCAAAUUGGAUGAAUA-3'; unrelated control siRNA: 5'-UUCUUAGCAAGACUGGUCUCUAGGG-3'. Lsd1 inhibitor QC6688 was applied to differentiated cells at 100 nM (in EtOH) for 3 days. EtOH was used as a vehicle. Brown adipocytes were either harvested and snap-frozen for RNA, protein, and chromatin immunoprecipitation experiments, fixed for 1 h with 4 % PFA and stained with Oil Red O, or fixed for 5 min with 1 % PFA for chromatin immunoprecipitation experiments (see bellow).
Chromatin immunoprecipitation (ChIP) and ChIP sequencing (ChIP-seq)
Chromatin immunoprecipitation experiments were performed using anti-Lsd1 (20752, Schüle laboratory), antiNrf1 (Abcam, ab55744), anti-Rcor1 (Abcam, ab32631), anti-Rcor3 (Abcam, ab76921), H3K9me2 (Diagenode, Mab-154-050), or H3K4me2 (Diagenode, CS-035-100) antibodies, or a rabbit IgG negative control on protein GSepharose 4B (GE Healthcare) essentially as described (Metzger et al., 2008) . For ChIP experiments, ChIPed DNA was processed by qPCR analyses with the primers described in Table S5 . For ChIP-seq analysis, libraries were prepared from Lsd1-immunoprecipitated DNA according to standard methods. ChIP-seq libraries were sequenced using a HiSeq 2000 (Illumina) and mapped to the mm10 reference genome using bowtie 2 (Langmead et al., 2009 ). Data were analyzed using the peak finding algorithm MACS 1.41 (Zhang et al., 2008 ) using input as control. All peaks with a FDR greater than 0.3 % were excluded from further analysis. The uniquely mapped reads were used to generate the genome-wide intensity profiles, which were visualized using the IGV genome browser (Thorvaldsdottir et al., 2012) . HOMER (Heinz et al., 2010) was used to annotate peaks, to calculate overlaps between different peak files, and for motif searches. The genomic features (promoter, exon, intron, 3' UTR, and intergenic regions) were defined and calculated using Refseq and HOMER.
Histological and immunofluorescence analysis
Tissues were fixed in 10 % buffered formalin and embedded in paraffin. 5 µm paraffin sections were deparaffinised and rehydrated. Hematoxylin and eosin staining was performed as described . For immunofluorescence analyses, rehydrated sections were boiled in antigen unmasking solution (Tris buffer pH 9) for 20 min, cooled to room temperature, washed 3 times with PBS, 0.1 % Triton-X100 for 5 min, blocked for 1 h in 5 % FBS (Gibco, 10270-106) in PBS, 0.1 % Triton-X100, and incubated overnight at 4°C with anti-Lsd1 (1/1000), anti-Ucp1 (Abcam, ab10983, 1/500), or anti-Perilipin (Abcam, ab3526, 1/400) antibodies. Slides were then incubated with secondary antibody conjugated to Alexa488 (Invitrogen, 1/400) and mounted in aqueous medium (Fluoromount-G, SouthernBiotech, 0100-01) with DAPI (Sigma, D-9542, 1/1000). Ultrastructural analyses were performed as described .
Measuring activities of metabolic enzymes
Glucose uptake, hexokinase, phosphofructokinase, enolase, lactate dehydrogenase, glutamate oxaloacetic transaminase, NAD + /NADH ratio, hormone-sensitive lipase, LPL, and fatty acid synthase activities were assessed by the Glucose Uptake Assay Kit (ab136955, abcam), Hexokinase Colorimetric Assay Kit (MAK091, Sigma), the Phosphofructokinase Colorimetric Assay Kit (MAK093, Sigma), the Enolase Activity Colorimetric/Fluorometric Assay Kit (K691-100, Bio Vision), the Lactate Dehydrogenase Activity Assay Kit (Sigma, MAK066), the Glutamate-oxaloacetate transaminase kit (K753-100, Bio Vision), the NAD/NADH Assay Kit (ab65348, abcam), the Lipase Activity Assay Kit (MAK046, Sigma), the LPL Activity Assay kit (MAK109, Sigma), and Fatty Acid Synthase ELISA kit (ABIN425666, antibodies-online), respectively. All activities were measured using 20-50 mg of BAT according to the manufacturer recommendations.
Metabolomic and lipidomic analyses
Tissue samples were grinded with a Retsch MM440 instrument and further extracted as described in . LC-MS measurements were performed using a Waters ACQUITY UPLC system coupled to a Thermo-Fisher QExactive mass spectrometer. Lipophilic compounds were separated using a C8 and hydrophilic compounds using a C18 reverse phase column, respectively. The mobile phase composition and electrospray parameters are described in ). Chromatograms were recorded in survey MS mode (Mass Range [100 -1500]) for hydrophilic compounds and in DDA MS/MS (40 eV collision energy) mode for lipophilic compounds. GC-MS measurements were performed as follows. An aliquot of lower polar extraction phase was dried and the dry residue was sequentially derivatized by methoxyamine/MSTFA and injected onto DB35 GC column (Agilent Technologies GC machine) coupled to Leco Pegasus HT mass spectrometer with EI ionization source. Gas elution was performed for two minutes at 85 °C with a further temperature gradient of 15 °C per minute untill a final temperature of 360 °C was reached. Peak-picking and background removal of the LC-MS data from measurements of hydrophilic extraction phase was accomplished with the Genedata REFINER MS® 7.5 software. Chromatogram alignment and filtering were completed using in-house R-based software. Filtering included removal of isotopic peaks, in-source fragments, and additional lower intense adducts of the same analyte. The annotation of the content of the sample was accomplished by matching the extracted data from the chromatograms with our library of reference compounds in terms of accurate mass and retention time, and the most abundant adduct was used for relative quantification of a metabolite. For GC-MS data of the same extraction phase NetCDF files were exported from the Leco Pegasus software to "R". The package TargetSearch was used to transform retention time to retention index (RI), to align the chromatograms, extract the peaks, and annotate them by comparing the spectra and the RI to the Golm metabolome database. A unique mass was used to relatively quantify each identified metabolite. For those metabolites, which were annotated in both GC-MS and LC-MS data the value with smallest deviation was kept. Peak-picking of the LC-MS/MS data from measurements of the lipophilic extraction phase was accomplished with the Genedata REFINER MS® 7.5 software without alignment. Identification of lipid species was performed using output.mgf files with dedicated in-house R-based software. Acyl composition of di-and triacylglycerols was established from the [Acyl + NH4] neutral loss in positive ion mode using a pre-formed library of accurate masses for all possible precursor and fragment peaks.
Mitochondrial respiration
10 mg (wet weight) of BAT were minced and incubated in Mir05 with 50 µg/mL Saponin for 30 min at 37 °C to permeabilize the cell membrane. Mir05 is composed of 0.5 mM EGTA, 3 mM MgCl 2 , 60 mM K-lactobionate, 20 mM Taurine, 10 mM KH 2 PO 4 , 20 mM HEPES, 110 mM Sucrose, and 1 g/L BSA fatty acid free. Respiration of permeabilized brown adipocytes was measured by high-resolution respiratory using Oxygraph-2K (OROBOROS INSTRUMENTS, Innsburk, Austria) at 37 °C in 2 mL glass chambers. For each experiment, one control mouse and one Lsd1 cKO mouse were processed in parallel in the 2 chambers. Mitochondrial respiration was assessed in Mir05 buffer supplemented with 5 mM glutamate and 2 mM malate substrates to activate mitochondrial complex I. After stabilization of mitochondrial respiration, 10 mM succinate were added to activate complex II. Maximal respiration rate was then recorded. 0.5 µM rotenone were finally added to inactivate mitochondrial complex I and measure complex II specific activity. Respiration rates were expressed in pmol / s and reported to 1 mg of tissue. Results presented correspond to maximal mitochondrial respiration rate. Alternatively, mitochondrial respiration was analyzed using 100 µM palmitoyl-L-carnitin as substrate.
